HPV Oral Cancer Risk: Why the Old Risk Model Fails

Risk assessment for oral and oropharyngeal cancer is still taught around a patient who is increasingly not the one presenting. The tobacco-and-alcohol model remains valid for one form of the disease and close to useless for the other. Understanding which is which changes how a practice screens.

These are two different diseases

Oral and oropharyngeal squamous cell carcinoma now splits into two clinically distinct entities with different causes, different patient populations, different anatomy and different outcomes.

HPV-negative disease is the classic presentation. It is driven by tobacco and alcohol, often with a synergistic effect between them, typically in patients over 60 with a long exposure history. It tends to arise in the oral cavity proper: lateral tongue, floor of mouth, the sites a thorough visual and tactile exam is designed to reach.

HPV-positive disease is the one driving the increase. The CDC attributes 60 to 70 percent of United States oropharyngeal cancers to HPV, with HPV-16 responsible for roughly 60 percent of oropharyngeal squamous cell carcinoma in tissue-registry analysis. It favors the tonsillar tissue and base of tongue, and it appears in patients who look low-risk on every traditional measure.

The distinction is significant enough that staging was separated. The AJCC eighth edition introduced a distinct staging system for p16-positive oropharyngeal cancer, because applying the old system produced misleading stage-for-stage prognosis. HPV-positive disease generally responds better to treatment and carries a more favorable outlook than HPV-negative disease at equivalent stage.

Who is actually at elevated risk

For HPV-positive oropharyngeal cancer the dominant demographic signals are sex and age. Of the 18,917 oropharyngeal squamous cell carcinoma cases the CDC recorded in 2015, 82 percent occurred in men. Oral HPV carriage itself is unevenly distributed, at roughly 10 percent of men against 3.6 percent of women, and rises with age.

Beyond that, the meaningful risk modifiers are lifetime number of oral sexual partners and anything that impairs viral clearance, including immunosuppression. Tobacco is not the primary driver here, though it is not neutral either, and there is evidence that smoking alongside HPV infection worsens outcomes.

For HPV-negative disease the established drivers are unchanged: tobacco in all its forms, heavy alcohol use, betel quid, and the combination of tobacco with alcohol.

Why this should not change who you screen

There is a tempting and wrong conclusion available here, which is to use this risk information to decide which patients get a thorough head and neck exam.

Do not do that. The defining operational feature of HPV-positive disease is that it presents in patients who screen as low-risk. A 47-year-old man who has never smoked, drinks socially, flosses, and has no complaint is precisely the profile now driving the increase. Any protocol that allocates examination effort by traditional risk score will systematically underexamine exactly the population it most needs to reach.

Risk stratification has a legitimate use, but it is not in deciding who gets examined. It belongs in the conversation, in the index of suspicion applied to an ambiguous finding, and in how quickly a persistent symptom converts into a referral rather than a watch-and-wait.

What actually reduces risk

Three levers, only one of which is new.

Vaccination. The 9-valent vaccine covers HPV-16 along with types 18, 31, 33, 45, 52 and 58. CDC recommends it at ages 11 to 12, catch-up through 26, and shared clinical decision-making for adults 27 through 45. Because oropharyngeal disease develops years after exposure, population-level effects will take time to appear. Vaccination questions belong with the patient’s physician.

Tobacco and alcohol reduction. Still the highest-yield intervention for HPV-negative disease, and still worth raising even though it does not address the HPV-driven increase.

A systematic examination. The only lever a dental practice controls directly. Given a disease that presents without risk markers, in anatomy that is easy to skip, often with a neck node before a visible lesion, the countermeasure is consistency rather than selectivity.

What that looks like in practice

• Examine every adult patient the same way at every recall, independent of risk score.
• Include deliberate extraoral neck palpation. For HPV-positive disease it may outperform intraoral inspection.
• Inspect tonsillar pillars and base of tongue deliberately, with retraction, not in passing.
• Ask about unilateral sore throat, referred ear pain, swallowing difficulty or voice change persisting beyond two to three weeks.
• Document what was examined and when, so change over time is visible rather than remembered.
• Define the referral pathway in advance so a suspicious finding does not become a rescheduling problem.

No device detects HPV, and none is a substitute for biopsy or referral. Fluorescence visualization identifies changes in tissue fluorescence associated with mucosal abnormality, which is a different and narrower claim. What it offers a practice is structure: a repeatable exam and a documented record. Practices wanting that structure can review the VELscope Mantis screening device, though the protocol discipline above is the part that carries most of the benefit.

Prognosis, surveillance, and what patients will ask you for

Because HPV-positive disease generally carries a better outlook, more of these patients survive treatment and return to routine dental care. That makes post-treatment surveillance something dental teams encounter, even though they do not run it.

Surveillance has changed. Plasma circulating tumor HPV DNA has emerged as a sensitive and specific biomarker for HPV-associated oropharyngeal squamous cell carcinoma. In a prospective trial published in the Journal of Clinical Oncology, longitudinal monitoring produced a negative predictive value of 100 percent across patients with undetectable levels at every post-treatment time point, and two consecutive positive results showed high positive predictive value for recurrence. A commercially available tissue-modified viral HPV DNA assay has been in United States clinical use since early 2020.

Two qualifications matter, and both come up chairside.

First, this is surveillance, not screening. It is used in patients already diagnosed and treated, to detect recurrence earlier than imaging or clinical examination alone. It is not a test for HPV in a healthy patient, and there is still no approved screening test for oral HPV in asymptomatic people. When a patient asks whether he can just get a blood test instead of an exam, this is the distinction to draw.

Second, the evidence base is still maturing. Commentary in the same journal has noted meaningful open questions and the absence of National Comprehensive Cancer Network guidelines governing its use. It is increasingly used rather than settled.

The practical implication for a dental practice is narrow but real. A patient in post-treatment follow-up for HPV-positive oropharyngeal cancer is at elevated risk of both recurrence and treatment sequelae including xerostomia, radiation caries and trismus. He needs continued head and neck examination at recall, coordination rather than duplication with his oncology team, and a low threshold for reporting new unilateral symptoms upward.

This article is general clinical information for dental professionals and is not a substitute for diagnosis, individual clinical judgment, or referral. Epidemiological figures are drawn from the CDC and the American Cancer Society.